In a statement, the European Medicines Agency stated that it is based on preliminary data from laboratory research and research in adults. It compared Hipra’s booster shot with the vaccine made in Pfizer-BioNTech. Early results indicate that Hipra may be effective against COVID-19, which includes the highly infectious omicron variant.
Hipra, a protein-based vaccine, is manufactured using the same technology as Novavax COVID-19 vaccine. It was approved by the EMA in December. It contains two forms of coronavirus’ spike proteins that were created in a laboratory. These are meant to stimulate an immune response after a person has been immunized.
Hipra is meant to act as a booster shot for people who have received a vaccine containing a messenger RNA or a vector-based virus, such as those made by Johnson & Johnson and AstraZeneca. Hipra’s focus has been on vaccines for animals until now.
Scientists believe that different vaccine types can boost the immune system. Many countries have adopted a mix-and-match strategy for COVID-19 vaccination.
Hipra is reported to have sold millions of its vaccines to Vietnam. It has also estimated that it could produce 600 million doses each year.
